Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
SLNO Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SLNO Stock 12 Month Forecast
Average Price Target
$117.36
▲(83.81% Upside)
| Highest Price Target$145.00 | Average Price Target$117.36 | Lowest Price Target$106.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wells Fargo
$123→$106
Buy
66.01%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$115
Buy
80.11%
Upside
Reiterated
11/05/25
Cantor Fitzgerald
$123
Buy
92.64%
Upside
Reiterated
11/04/25
TD Cowen
$120
Buy
87.94%
Upside
Reiterated
11/04/25
Goldman Sachs
$125
Buy
95.77%
Upside
Initiated
10/07/25
Piper Sandler
$145
Buy
127.09%
Upside
Reiterated
10/03/25
H.C. Wainwright
$110
Buy
72.28%
Upside
Reiterated
09/25/25
Positive Outlook for Soleno Therapeutics Amid Competitive Setback and Strong VYKAT XR PerformanceValuation and Risks. We have employed a discounted cash flow (DCF)-based approach to assess Soleno's prospects. This utilizes a 10% discount rate, 2% terminal growth rate and 29.84% effective tax rate. We ascribe a 100% probability of U.S. regulatory approval to Soleno's sole marketed product, VYKAT XR (formerly DCCR). Given these parameters, we derive a total firm value of $6.25B, which translates into a 12-month price objective of $110 per share assuming ~56.8M shares outstanding as of mid-2026. Risks include, but are not limited to: (1) slower-than-expected U.S.
Robert W. Baird
$121
Buy
89.51%
Upside
Reiterated
09/25/25
Kate Dellorusso
LifeSci CapitalNot Ranked
LifeSci Capital
$120
Buy
87.94%
Upside
Reiterated
09/10/25
LifeScience Cap's Optimistic Outlook on Soleno Therapeutics: Vykat XR's Promising Market Potential and Expansion PlansWe are assuming coverage of SLNO with an Outperform rang, $120 PT. In late March, the FDA approved Vykat XR (diazoxide choline extended-release [DCCR]) for the treatment of hyperphagia associated with Prader Willi syndrome (PWS), a debilitang disease marked by the insaable desire to eat. Early launch metrics point to robust uptake by paents and physicians: Q2 net sales of $32.7M, 646 start forms, and 295 new prescribers in just the first quarter of launch. Market access is building quickly (~1/3 covered lives in the U.S.), and we expect connued growth as familiarity with the product profile and reimbursement improves.
Oppenheimer
$110
Buy
72.28%
Upside
Reiterated
08/25/25
Guggenheim
$97→$106
Buy
66.01%
Upside
Reiterated
08/06/25
Laidlaw
$75→$105
Buy
64.45%
Upside
Reiterated
03/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
$123→$106
Buy
66.01%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$115
Buy
80.11%
Upside
Reiterated
11/05/25
Cantor Fitzgerald
$123
Buy
92.64%
Upside
Reiterated
11/04/25
TD Cowen
$120
Buy
87.94%
Upside
Reiterated
11/04/25
Goldman Sachs
$125
Buy
95.77%
Upside
Initiated
10/07/25
Piper Sandler
$145
Buy
127.09%
Upside
Reiterated
10/03/25
H.C. Wainwright
$110
Buy
72.28%
Upside
Reiterated
09/25/25
Positive Outlook for Soleno Therapeutics Amid Competitive Setback and Strong VYKAT XR PerformanceValuation and Risks. We have employed a discounted cash flow (DCF)-based approach to assess Soleno's prospects. This utilizes a 10% discount rate, 2% terminal growth rate and 29.84% effective tax rate. We ascribe a 100% probability of U.S. regulatory approval to Soleno's sole marketed product, VYKAT XR (formerly DCCR). Given these parameters, we derive a total firm value of $6.25B, which translates into a 12-month price objective of $110 per share assuming ~56.8M shares outstanding as of mid-2026. Risks include, but are not limited to: (1) slower-than-expected U.S.
Robert W. Baird
$121
Buy
89.51%
Upside
Reiterated
09/25/25
Kate Dellorusso
LifeSci CapitalNot Ranked
LifeSci Capital
$120
Buy
87.94%
Upside
Reiterated
09/10/25
LifeScience Cap's Optimistic Outlook on Soleno Therapeutics: Vykat XR's Promising Market Potential and Expansion PlansWe are assuming coverage of SLNO with an Outperform rang, $120 PT. In late March, the FDA approved Vykat XR (diazoxide choline extended-release [DCCR]) for the treatment of hyperphagia associated with Prader Willi syndrome (PWS), a debilitang disease marked by the insaable desire to eat. Early launch metrics point to robust uptake by paents and physicians: Q2 net sales of $32.7M, 646 start forms, and 295 new prescribers in just the first quarter of launch. Market access is building quickly (~1/3 covered lives in the U.S.), and we expect connued growth as familiarity with the product profile and reimbursement improves.
Oppenheimer
$110
Buy
72.28%
Upside
Reiterated
08/25/25
Guggenheim
$97→$106
Buy
66.01%
Upside
Reiterated
08/06/25
Laidlaw
$75→$105
Buy
64.45%
Upside
Reiterated
03/27/25
Best Analysts Covering Soleno Therapeutics
1 Month
xxx
Success Rate
5/8 ratings generated profit
Average Return
+7.61%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +7.61% per trade.
3 Months
xxx
Success Rate
8/10 ratings generated profit
Average Return
+91.91%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +91.91% per trade.
1 Year
Success Rate
9/10 ratings generated profit
Average Return
+191.22%
reiterated a buy rating 2 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +191.22% per trade.
2 Years
xxx
Success Rate
9/10 ratings generated profit
Average Return
+199.91%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +199.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SLNO Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
6
11
22
25
22
Buy
15
11
9
4
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
22
31
29
22
Each month's total comprises the sum of three months' worth of ratings.
SLNO Financial Forecast
SLNO Stock Forecast FAQ
What is SLNO’s average 12-month price target, according to analysts?
Based on analyst ratings, Soleno Therapeutics Inc’s 12-month average price target is 117.36.
What is SLNO’s upside potential, based on the analysts’ average price target?
Soleno Therapeutics Inc has 83.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SLNO a Buy, Sell or Hold?
Soleno Therapeutics Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Soleno Therapeutics Inc’s price target?
The average price target for Soleno Therapeutics Inc is 117.36. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $145.00 ,the lowest forecast is $106.00. The average price target represents 83.81% Increase from the current price of $63.85.
The highest analyst price target is $145.00 ,the lowest forecast is $106.00. The average price target represents 83.81% Increase from the current price of $63.85.
What do analysts say about Soleno Therapeutics Inc?
Soleno Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of SLNO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.